Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Tryptamine Therapeutics ( (AU:ENP) ) is now available.
Entropy Neurodynamics reported a pivotal quarter marked by the successful enrolment and full dosing of the first patient in its world-first clinical trial of TRP-8803, an IV psilocin therapy for Binge Eating Disorder, conducted with Swinburne University. The patient completed two monitored infusions that demonstrated controlled, repeatable psychedelic exposure and favourable tolerability, with three of the planned 12 patients now enrolled and early data from the initial participant expected in the coming weeks. Financially, the company strengthened its balance sheet through a A$6.1 million placement and receipt of an A$847,186 R&D tax incentive, with further non-dilutive funding anticipated, providing capital to accelerate TRP-8803 clinical, manufacturing and regulatory programs. Together with a corporate rebrand to Entropy Neurodynamics and plans to launch a larger multi-indication trial this quarter, these developments underscore the company’s ambition to position TRP-8803 as a differentiated neuropsychiatric platform and reinforce its execution capabilities in the emerging psychedelic medicine sector.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
More about Tryptamine Therapeutics
Entropy Neurodynamics Limited (ASX: ENP) is a Melbourne-based, clinical-stage biotechnology company specialising in psychedelic-based, biomarker-driven neuropsychiatric therapies. Its lead asset, TRP-8803, is an intravenously infused psilocin formulation being developed as a precision-dosed treatment for conditions such as Binge Eating Disorder, with a strategic focus on controlled, repeatable psychedelic delivery over traditional oral approaches.
Average Trading Volume: 2,434,191
Technical Sentiment Signal: Sell
Current Market Cap: A$51.57M
For an in-depth examination of ENP stock, go to TipRanks’ Overview page.